{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:22:10Z","timestamp":1756894930761,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Leipzig"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Interim [<jats:sup>18<\/jats:sup>F]fluoro-deoxyglucose-positron emission tomography predicts outcome in peripheral T-cell lymphoma (PTCL). We compared two quantitative evaluation methods.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Interim scans from 43 patients with anaplastic lymphoma kinase-negative PTCL from the \u2018Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas\u2019 trial were re-analyzed by qPET (relating residual lymphoma-related uptake to liver uptake) and \u2206SUV<jats:sub>max<\/jats:sub> (relating interim scan to baseline scan). The endpoint was progression-free survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>qPET and \u2206SUV<jats:sub>max<\/jats:sub> were closely correlated (Pearson\u2019s <jats:italic>r<\/jats:italic>\u2009=\u20090.627). Up to the 60<jats:sup>th<\/jats:sup> percentile of values ranked by increasing residual activity, the positive predictive value for progression or death increased from 60 to 95%, with stable negative predictive values (NPV) of 60%. Beyond the 60<jats:sup>th<\/jats:sup> percentile, the NPV decreased to 40%. qPET\u2009\u2265\u20092 and \u2206SUV<jats:sub>max<\/jats:sub>\u2009&lt;\u200950% identified high-risk populations comprising 41.9% and 39.5% of patients, with 3-year progression-free survival rates of 5.6% (95% confidence interval, 0.8\u201337.3) and 0%, respectively, as compared to 63.7% (47.4\u201385.8) and 61.3% (45.1\u201383.3) in low-risk patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>qPET and \u2206SUV<jats:sub>max<\/jats:sub> identify large fractions of PTCL patients destined to experience treatment failure. qPET may be preferred because it requires a single PET scan, halving the diagnostic effort.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13550-021-00827-1","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T20:02:31Z","timestamp":1631649751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Quantitative evaluation of interim positron emission tomography in peripheral T-cell lymphoma"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-4880","authenticated-orcid":false,"given":"Lars","family":"Kurch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"D\u00fchrsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"H\u00fcttmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas W.","family":"Georgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regine","family":"Kluge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Hasenclever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"key":"827_CR1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstr\u00f6m J, Jerkeman M, et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014. https:\/\/doi.org\/10.1182\/blood-2014-04-573089.","journal-title":"Blood"},{"key":"827_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8093","author":"U D\u00fchrsen","year":"2018","unstructured":"D\u00fchrsen U, M\u00fcller S, Hertenstein B, et al. Positron emission tomography-guided therapy of aggressive non-hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018. https:\/\/doi.org\/10.1200\/JCO.2017.76.8093.","journal-title":"J Clin Oncol"},{"key":"827_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2697","author":"C Schmitz","year":"2020","unstructured":"Schmitz C, Rekowski J, M\u00fcller SP, et al. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: a subgroup analysis of the PETAL trial. Hematol Oncol. 2020. https:\/\/doi.org\/10.1002\/hon.2697.","journal-title":"Hematol Oncol"},{"key":"827_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.5229","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014. https:\/\/doi.org\/10.1200\/JCO.2013.53.5229.","journal-title":"J Clin Oncol"},{"key":"827_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2715-9","author":"D Hasenclever","year":"2014","unstructured":"Hasenclever D, Kurch L, Mauz-K\u00f6rholz C, et al. qPET \u2013 a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014. https:\/\/doi.org\/10.1007\/s00259-014-2715-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"827_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231027","author":"TW Georgi","year":"2020","unstructured":"Georgi TW, Kurch L, Hasenclever D, et al. Quantitative assessment of interim PET in Hodgkin lymphoma: an evaluation of the qPET method in adult patients in the RAPID trial. PLoS ONE. 2020. https:\/\/doi.org\/10.1371\/journal.pone.0231027.","journal-title":"PLoS ONE"},{"key":"827_CR7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.255034","author":"L Kurch","year":"2020","unstructured":"Kurch L, Andreas H, Georgi TW, et al. Interim positron emission tomography in diffuse large B-cell lymphoma. J Nucl Med. 2020. https:\/\/doi.org\/10.2967\/jnumed.120.255034.","journal-title":"J Nucl Med"},{"key":"827_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.8195","author":"MJ Maurer","year":"2017","unstructured":"Maurer MJ, Ellin F, Srour L, et al. International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol. 2017. https:\/\/doi.org\/10.1200\/JCO.2017.73.8195.","journal-title":"J Clin Oncol"},{"key":"827_CR9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.247924","author":"R Kluge","year":"2021","unstructured":"Kluge R, Wittig T, Georgi TW, et al. Comparison of interim PET response to second-line versus first-line treatment in classic Hodgkin lymphoma: contribution to the development of response criteria for relapsed or progressive disease. J Nucl Med. 2021. https:\/\/doi.org\/10.2967\/jnumed.120.247924.","journal-title":"J Nucl Med"},{"key":"827_CR10","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1182\/blood.2020008825","volume":"137","author":"N Schmitz","year":"2021","unstructured":"Schmitz N, Truemper LH, Bouabdallah K, et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood. 2021;137:2646. https:\/\/doi.org\/10.1182\/blood.2020008825.","journal-title":"Blood"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-021-00827-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-021-00827-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-021-00827-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T20:03:58Z","timestamp":1631649838000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-021-00827-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["827"],"URL":"https:\/\/doi.org\/10.1186\/s13550-021-00827-1","relation":{},"ISSN":["2191-219X"],"issn-type":[{"type":"electronic","value":"2191-219X"}],"subject":[],"published":{"date-parts":[[2021,9,14]]},"assertion":[{"value":"17 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The PETAL trial (ClinicalTrials.gov NCT00554164; EudraCT 2006-001641-33) was a multicenter study for newly diagnosed aggressive non-Hodgkin lymphomas. The study was approved by the Federal Institute for Drugs and Medical Devices and the ethics committees of all participating sites. All patients gave written informed consent including their permission to use their data for post-hoc scientific analyses.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"UD received institutional research grants and honoraria from Amgen Germany and Roche Pharma. No other potential conflicts of interest relevant to this article exist.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}